Morgan Stanley initiated coverage on shares of ZEALAND PHARMA (NASDAQ:ZEAL) in a research note issued to investors on Tuesday morning, MarketBeat Ratings reports. The firm issued an overweight rating and a $28.00 price target on the stock.

Several other equities analysts also recently issued reports on ZEAL. Guggenheim assumed coverage on shares of ZEALAND PHARMA in a research note on Tuesday. They set a buy rating and a $28.00 price target for the company. Needham & Company LLC assumed coverage on shares of ZEALAND PHARMA in a research note on Tuesday. They set a buy rating and a $26.00 target price for the company.

Shares of ZEALAND PHARMA (ZEAL) opened at 20.12 on Tuesday. The company’s market cap is $614.91 million. ZEALAND PHARMA has a 12 month low of $16.07 and a 12 month high of $20.37. The firm’s 50 day moving average is $18.30 and its 200 day moving average is $18.30.

WARNING: “Morgan Stanley Initiates Coverage on ZEALAND PHARMA (ZEAL)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/09/morgan-stanley-initiates-coverage-on-zealand-pharma-zeal.html.

Receive News & Stock Ratings for ZEALAND PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA and related stocks with our FREE daily email newsletter.